Abstract-The controversy over beneficial versus harmful effects of salt on cardiovascular outcomes may be caused by different effects of salt on intermediate phenotypes of hypertension not characterized in epidemiological studies. Hence, we investigated acute effects of salt on oxidative stress in hypertensive subjects classified as salt sensitive (SS, nϭ14) or salt resistant (SR, nϭ13) by an inpatient protocol of salt loading (460 mmol NaCl) and salt depletion (10 mmol NaCl and furosemide). Oxidative stress was assessed by measuring the plasma isoprostane 8-iso-PGF2␣. SS had lower plasma renin activity, higher aldosterone/renin ratios, and exaggerated endothelin and catecholamine responses to salt depletion compared with SR. Baseline lipid-bound isoprostanes (749Ϯ70 pmol/L) were 83% of the total and were slightly but not significantly higher in SS than SR. Baseline free isoprostanes did not differ between groups. After salt loading, lipid-bound isoprostanes were higher in SS (945Ϯ106) than SR (579Ϯ57; PϽ0.01). Salt depletion significantly decreased them in SS (Ϫ174Ϯ84) and increased them in SR (ϩ129Ϯ58), equalizing their levels (771Ϯ61 versus 708Ϯ91; P value not significant). Free isoprostanes were decreased by salt depletion only if data in all of the patients were analyzed together. Total isoprostanes followed the pattern of the lipid-bound fraction. Correlations between salt depletion-induced changes in lipid-bound isoprostanes, plasma renin activity (rϭ0.45; PϽ0.02), and aldosterone/renin ratios (rϭϪ0.41; PϽ0.04) suggested that the more SS the patient, the greater the reduction of oxidative stress by salt depletion. Our research is the first to show that salt affects oxidative stress acutely in humans, particularly in SS hypertension, which may explain the controversial results of epidemiological studies on salt and morbidity and may have implications for therapy. 
T here is overall agreement that salt intake is a major determinant of population blood pressure (BP) and prevalence and severity of hypertension. 1 In contrast, there is major disagreement about the effects of salt on cardiovascular outcomes. Many studies have shown that salt is a cardiovascular risk factor independent of BP 2, 3 and that it relates to left ventricular mass, 4 stroke, 5 conduit artery stiffness, 6 renal disease, 7 and cardiovascular morbidity and mortality. 8 However, others have reported that salt depletion, rather than salt, is associated with the highest incidence of myocardial infarction and total cardiovascular events in hypertensive patients, 9 perhaps because of activation of the renin-angiotensin system. 10 Two large epidemiological studies, conducted by different groups on the same database (National Health and Nutrition Examination Survey I), provided a clue to the reason underlying this controversy. Although one of them reported highest allcause mortality for the lowest salt intake, 11 the other found an opposite, direct relationship between salt intake and all-cause and cardiovascular mortalities. 12 The major difference between these 2 studies was that the latter gave due consideration to the possibility that 1 hypertensive phenotype (ie, obesity) determined the role of salt on mortality. Hence, it is likely that conflicting results of epidemiological research reflect opposite effects of salt in hypertensive subjects with many different intermediate phenotypes that have not been characterized in these studies. This is supported by the observation that salt sensitivity of BP carries prognostic implications. 13 We speculated that the hypertensive intermediate phenotype most likely to be differentially affected by salt in terms of prognosis is that of salt-sensitive (SS) versus salt-resistant (SR) hypertension. In experimental SS hypertension, high salt intake produces increased renal, 14 -17 myocardial, 17, 18 vascular, 19 and hepatic 20, 21 oxidative stress, which can be detected by serum markers. 17, 22 Because in these animal models antioxidants prevent the rise of BP, improve established hypertension, 19, 20 and ameliorate renal and vascular damage, 16, 19, 22 it is likely that oxidative stress mediates their hypertension and target organ damage.
Therefore, we investigated the prevailing level of and the effect of salt on oxidative stress in SS and SR hypertensive patients, using measurements of the isoprostane 8-iso-prostaglandin (PG)F2␣, which is a sensitive and specific marker for oxidative stress in experimental models 23 and human disease. 24 
Methods
After protocol approval by the Institutional Review Board and subjects' informed consent, 27 hypertensive patients (systolic BP Ͼ140 mm Hg, diastolic Ͼ90 mm Hg, or on antihypertensive treatment) were recruited to undergo determination of salt sensitivity of BP with the protocol validated by Weinberger et al. 25 Briefly, after 2 weeks off therapy and on usual salt intake, patients were admitted to the Clinical Research Center where they underwent 24-hour salt loading (160 mmol NaCl diet ϩ2L intravenous saline 8:00 AM to 12:00 PM) followed by 24-hour salt depletion (10 mmol NaCl diet and 40 mg oral furosemide at 8:00 AM, 12:00 PM, and 4:00 PM).
Casual baseline BP was measured before admission with mercury sphygmomanometers (seated, after 5 minutes resting, in triplicate). Ambulatory monitors (Spacelabs 90207) were used to measure BP during admission (every 15 minutes, from 12:00 PM to 10:00 PM, on both protocol days). Patients were classified as SS if the average systolic BP of the salt-depletion day was Ն10 mm Hg lower than that of the salt-loading day.
Body mass index (in kg/m 2 ), routine laboratory tests, plasma lipids, and an ECG were obtained at baseline. Left ventricular hypertrophy was diagnosed if the Cornell index [(RaVLϩSV3)mmϫQRSms] was Ͼ2440.
Hormones, vasoactive substances, and isoprostanes were measured at baseline (8:00 AM of the first day, before high-salt diet and saline infusion), after the salt-loading period (8:00 AM of the second day, before furosemide and low-salt diet), and after salt depletion (8:00 AM of the third day, at the end of the protocol). Measurements included plasma renin activity (PRA), plasma aldosterone, and plasma endothelin by previously described radioimmunoassays 26 -28 and plasma catecholamines by radioenzymatic assay (BioTrak TRK 995, Amersham).
Plasma isoprostanes (free and total) were measured with a previously described enzymatic immunoassay (Cayman Chemical). 29 Briefly, blood samples were collected in chilled EDTA tubes, immediately centrifuged at 4°C, and stored at Ϫ80°C until assayed. All of the thawed plasma aliquots were eluted in absolute methanol, whereas those for measurement of total isoprostanes were also subjected to 15% KOH hydrolysis (incubation for 1 hour at 38°C) to deesterify the bound fraction. The final eluents were poured into water/buffer solution on ice for pH adjustment to 3.1Ϯ0.5. Extraction was performed on Sep-Pak C-18 columns, with washes of water and hexane. Isoprostanes were eluted with 99/1% ethyl-acetate/methanol, dried under nitrogen, and reconstituted into 1.0 mL of assay buffer. Samples and standard were added in triplicate to the assay plate followed by tracer and antibody. After overnight incubation at room temperature and washings with buffer, Ellmans reagent was added. Developed color was read at 405 nm, and values in the sample derived from %B/Bo. The lipid-bound or esterified isoprostane fraction was calculated by subtracting measured free from measured total isoprostanes. Intraassay coefficient of variability was 2.25Ϯ0.6% (free) and 12.6Ϯ3.8% (total isoprostanes). Interassay variability (several control samples run monthly for Յ19 months) was Ͻ10%, and the antibody cross reactivity was Ϸ20% for 8-isoPGF3␣ but Ͻ4% (mostly Ͻ1%) for another 23 prostanoids. The coefficient of variation for the results of this study (35% to 42% in patient subgroups) are well within those reported by others with mass spectrometry 30 and by our group with the same method in pigs. 29 Twenty-four-hour urine collections were used to assess the effects of the protocol on sodium balance (intake minus urine excretion) during the salt-loading and salt-depletion periods.
Data are presented as meanϮSEM. Comparisons between means were made with unpaired t tests; changes within groups were analyzed with paired t tests and correlation coefficients with Pearson's method. These tests and single linear regression analyses were carried out with JMP software (version 3.2.6, SAS Institute). A P value Ͻ5% was used to reject the null hypothesis.
Results
Patients were 46Ϯ2 years of age, predominantly women (74%), with slightly more than half being black (56%). Although average baseline BP was within stage I of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure classification (152Ϯ4/93Ϯ2 mm Hg), 30% of patients had systolic BP Ͼ160 mm Hg and diastolic BP Ͼ100 mm Hg. Obesity (body mass index Ͼ30 kg/m 2 ) was present in 70% and current smoking in 37%. Elevated lowdensity lipoprotein cholesterol (for risk-tailored goal levels of 3.4 or 2.6 mmol/L) and decreased high-density lipoprotein cholesterol (below sex-dependent minimum normal values of 1.3 or 1.0 mmol/L) were present in 31% and 56% of subjects, respectively, whereas triglycerides were elevated (Ͼ1.7 mmol/L) in 35%. No patient had significant renal dysfunction (mean creatinine clearance 131Ϯ7 mL/min; range, 73 to 200 mL/min), and only 19% had left ventricular hypertrophy by ECG. There were no significant differences in any of these demographic and clinical characteristics between the SS and SR groups (Table 1) .
Using the 10 mm Hg cutoff for a fall in systolic BP from the salt-loaded to the salt-depleted state, 14 subjects were classified as SS (⌬ systolic BPϭϪ13.5Ϯ1.4 mm Hg; PϽ0.001) and 13 as SR (⌬ systolic BPϭϪ3.4Ϯ1.1 mm Hg; P value not significant). Table 2 shows that SS patients exhibited many of the previously described characteristics of this intermediate phenotype, including low PRA, 31,32 lack of suppression of aldosterone by a salt load, 32, 33 high aldosterone/renin ratios (ARR), 32, 34 and exaggerated responses of plasma endothelin 35 and catecholamines 32, 36 to salt depletion. These differences were present despite the fact that the positive salt balance after salt loading (ϩ132Ϯ21 mmol/24 h) and the negative one after salt depletion (Ϫ181Ϯ22 mmol/24 h) were not significantly different between the SS and SR groups (not shown).
In the 27 patients, baseline plasma level of total isoprostanes, measured before diet manipulation, that is, after pa- There were no statistically significant differences in any parameters between the SS and SR groups.
tients had been on their ad libitum salt intake, was 903Ϯ71 pmol/L. The free isoprostane fraction was 17% of the total (154Ϯ24), whereas the calculated lipid-bound fraction constituted the remaining 83% (749Ϯ70). At this stage, lipidbound and total isoprostanes were slightly but not significantly higher in SS than in SR (Figure 1 ). Levels of free isoprostanes were very similar in both groups.
The absolute levels of lipid-bound and free isoprostanes in SS and SR groups over the 3 conditions of the experiment are compared in the left panels of Figure 2 , whereas the magnitude and statistical significance of the changes produced by salt loading and salt depletion are given on the right. Free isoprostanes were not different between SS and SR in any of the 3 conditions of salt balance (Figure 2 , bottom left).
Although there was an apparent trend toward reduction of free isoprostanes by salt depletion in both groups (Figure 2 , bottom right), it did not reach statistical significance unless the 27 patients were analyzed together (Ϫ35Ϯ21 pmol/L; PϽ0.05).
Changes induced by salt loading on lipid-bound isoprostanes were of opposite direction (an increase of 93Ϯ111 in SS versus a decrease of Ϫ60Ϯ81 in SR; Figure 2 , top right) leading to significantly higher bound isoprostane levels in SS than in SR in the salt-replete state (945Ϯ106 versus 579Ϯ57; PϽ0.01; Figure 2 , top left). Salt-induced changes in total isoprostanes followed the same pattern (data not shown), most likely because of the fact that the lipid-bound fraction constitutes 83% of the total. Hence, total isoprostanes were also higher in SS than in SR in the salt-replete state (1085Ϯ102 versus 746Ϯ74 pmol/L; PϽ0.02).
Salt depletion produced statistically significant changes of opposite direction to those produced by salt loading in both groups. Hence, lipid-bound isoprostanes of SS were significantly reduced by salt deprivation, Ϫ174Ϯ84 pmol/L (PϽ0.03), whereas those of SR were significantly increased by 129Ϯ58 pmol/L (PϽ0.03). The difference between these 2 significant changes of opposite direction was also statistically significant by unpaired comparison (Figure 2, top right) . As a consequence of these changes, the levels of lipid-bound isoprostanes of SS and SR in the salt-depleted state (771Ϯ61 versus 708Ϯ91 pmol/L; P value not significant) were not only very similar but closer to each other than those observed when the patients were on ad libitum salt intake during the baseline period; 852Ϯ102 and 638Ϯ88, respectively (Figure 2 , top left). This suggests that our patients' unmeasured usual salt intake (before the experiment) was closer to that of the salt replete than to that of the salt-depleted period of the protocol. Again, total isoprostanes followed the same pattern as that of the bound fraction (data not shown), with values in the salt-depleted state being 888Ϯ60 in SS and 826Ϯ92 in SR, not significantly different and closer between groups than those during ad libitum salt intake (998Ϯ103 and 802Ϯ94, respectively).
We explored whether the response of bound isoprostanes to salt-depletion (ie, the major difference between SS and SR) correlated with any differential biochemical parameters between groups (ie, with any of their distinguishing phenotypic characteristics). Analyzing the 27 patients together, we found no relationship between this response and plasma endothelin, plasma catecholamines, or their stimulation by salt deprivation. In contrast, the change in bound isoprostanes produced by salt depletion correlated with PRA and ARR, such that those patients with more suppressed PRA, hence, higher ARR (both characteristics of our SS patients), had the largest reductions of bound isoprostanes by salt depletion. Figure 3 shows significant regressions for PRA and ARR of the saltreplete state, but similar relationships were present with PRA (rϭ0.36; Pϭ0.05) and ARR (rϭϪ0.39; PϽ0.05) of the baseline period (data not shown).
Analyzing the 2 groups separately, we found no correlation between the reduction of bound isoprostanes and the PRA response to salt depletion of SS (which was blunted, ϩ0.34Ϯ0.18 ngA I /L per second). In contrast, the increase of P value indicates statistical significance for the unpaired comparisons between groups; ns, not significant; RAAS, renin-angiotensin-aldosterone system; NE, norepinephrine; E, epinephrine. Figure 1 . Plasma levels of isoprostanes on ad libitum salt intake. Bound indicates calculated fraction esterified to plasma lipids; Free, measured free fraction; Total, measured total isoprostanes. Results in salt-sensitive patients are depicted by f and those in SR patients are given by Ⅺ. There were no statistically significant differences in isoprostanes between the 2 groups of patients.
bound isoprostanes and the larger PRA response to salt depletion of SR (ϩ0.74Ϯ0.26) were significantly correlated (rϭ0.70; PϽ0.001). This difference suggests that the reninangiotensin system participates in the response of bound isoprostanes to salt depletion, but only in SR, not SS patients.
Discussion
To our knowledge, this is the first report of an acute effect of changes in salt balance on oxidative stress in humans. Discovery of the isoprostanes, PGF2-like compounds formed by free-radical catalyzed, nonenzymatic metabolism of esterified arachidonic acid, has facilitated assessment of oxidative stress in humans, a task that was almost impossible before 1990. 37 The compound we measured, 8-iso-PGF2␣, is the most abundant F2-isoprostane produced in vivo, has been extensively studied, and is considered to be a sensitive and specific marker for oxidative stress in experimental animals 23 and human disease. 24 Baseline levels of free and bound isoprostanes in our patients were higher than those reported in normal volunteers. 30, 38 We cannot state that this represents increased oxidative stress in essential hypertension, because we did not study control subjects, and our measurements were made with a different methodology (enzyme immunoassay) from that used in the published normals (mass spectrometry). However, the proportion of plasma free and bound isoprostanes in our study (17% versus 83%) was similar to that obtained with mass spectrometry in normals (23% versus 77%). 30 Also, there are published reports of increased plasma lipid hydroperoxides in malignant and nonmalignant hypertensive patients 39 and of and SR (⅜ and Ⅺ) hypertensive subjects. Data on lipid-bound isoprostanes (Bound and ⌬Bound) are given in the top panels and those on free isoprostanes (Free and ⌬Free) are in the bottom. BL indicates baseline period, reflecting ad libitum salt intake; SL, after salt loading with dietary salt and saline infusion; and SD, after salt depletion by diet and furosemide. ⌬SL and ⌬SD are for the changes produced by salt loading and salt depletion, respectively. Symbols within bars are for the statistical significance (paired t test) of the changes within groups, whereas those between pairs of dots or bars (dotted connectors) are for the significance of the comparisons between groups (unpaired t test). *PϽ0.01, †PϽ0.03. Lack of a statistical symbol indicates lack of statistical significance for either within-or betweengroup comparisons. increased urinary excretion of isoprostanes in essential hypertensive subjects with concomitant obesity and dyslipidemia, 38 2 clinical characteristics that were very prevalent in our population.
The most striking observation of our study was that acute changes in salt balance produced qualitatively different effects on plasma isoprostanes in SS versus SR hypertensive subjects. Our major results were that there is increased oxidative stress during the salt-replete state in SS patients compared with SR and that salt depletion reduces it in SS to the extent of abolishing the difference between groups. We do not have an explanation for the reason that these changes were significant in the lipid-bound fraction but absent in the free fraction of plasma isoprostanes. Little is known about the dynamic relationship between these 2 fractions, but stimuli of oxidative stress produce an immediate increase of bound isoprostanes followed by a delayed appearance of the free fraction. 23 Therefore, it is conceivable that our different results for these 2 fractions are accounted for by the acute nature of our experimental design. Regardless of these somewhat different results with lipid-bound versus free isoprostanes, we have shown that there is increased oxidative stress in SS essential hypertension, not SR hypertension, during positive salt balance. This confirms our hypothesis, derived from studies in rodents with genetically (Dahl SS) 18 or hormonally (DOC-salt) 21 determined salt sensitivity of BP in which hypertension and target organ damage are highly dependent on oxidative stress. 16, 19, 20, 22 We can only speculate about the mechanism by which salt acutely increases oxidative stress in SS but not in SR hypertension. Clinical characteristics linked previously to increased oxidative stress in humans, such as left ventricular hypertrophy, 18 hypercholesterolemia, 40, 41 obesity, and atherogenic dyslipidemia reflecting insulin resistance 42 cannot explain the differences between SS and SR, because they were equally distributed in the 2 groups. We did not assess whether acute salt loading modified serum lipid concentrations, but this is a highly unlikely explanation for our results, because large differences in salt intake sustained for 30 days failed to modify lipid fractions in the participants of the Dietary Approaches to Stop Hypertension (DASH) sodium study. 43 Changes of isoprostanes by salt depletion correlated with PRA in a fashion suggestive of more oxidative stress in patients with renin suppression. This observation may seem paradoxical, because angiotensin II is a major stimulus for oxidative stress 44 via actions on membrane assembly of NADPH oxidase subunits. 45 However, it has been suggested that oxidative stress plays a role in hypertension at both ends of the salt balance spectrum, 46 that is, when the renin-angiotensin system is either stimulated or suppressed. For example, urinary excretion of isoprostanes and malonyldialdehyde of SpragueDawley rats can be increased by high-salt diet 47 or angiotensin II infusion 48 via stimulation of different NADPH oxidase subunits. Moreover, regulation of oxidative stress induced by angiotensin and salt may also be different. For example, angiotensin II stimulates, 48 whereas salt inhibits 47 mitochondrial superoxide dismutase. It is, therefore, clear that both angiotensin II and salt can stimulate oxidative stress, albeit by different molecular mechanisms. Only 2 of our 27 patients had PRA Ͼ1.39 ngA I /L per second (5 ngA I /mL per hour, the maximum "normal" limit in clinical medicine), whereas 14 had values consistent with "low-renin" hypertension (Ͻ0.18 ngA I /L per second or Ͻ0.65 ngA I /mL per hour). Hence, it is not surprising that in all patients, lower baseline PRA predicted decreased oxidative stress by salt removal. This suggests that when the renin-angiotensin system is not active, salt may be the major determinant of oxidative stress. In contrast, our SR patients had stimulation of lipid-bound isoprostanes by salt depletion. They had higher baseline PRA and greater PRA stimulation by salt depletion, and the latter correlated with the isoprostane response. This observation may reflect an effect of angiotensin II on the oxidative stress of subjects with preserved regulation of the renin-angiotensin system. Actually, it has been shown recently that angiotensin II infusion fails to stimulate isoprostanes in hypertensive subjects maintained on a low-salt intake. 49 This observation, together with our studies, suggests that oxidative stress of essential hypertension may reflect an inappropriate status of salt balance for any degree of activation of the renin-angiotensin system.
Finally, an intriguing possibility is raised by the fact that aldosterone is an independent stimulus for oxidative stress. 50 SS hypertensive subjects exhibit an inappropriate lack of suppression of aldosterone in response to a salt load, leading to high ARR. 34 In turn, aldosterone and endothelin have been implicated in the target organ damage of SS hypertension in both rodents 51, 52 and humans. 32 Therefore, it is not inconceivable that nonsuppressed aldosterone of SS during positive salt balance is responsible for oxidative stress in these patients. In our experiment, this was supported by the relationship between changes of isoprostanes by salt depletion and ARR, suggesting that oxidative stress is enhanced in patients in whom aldosterone is not suppressed by salt. Once elicited, oxidative stress can, in turn, produce endothelin release. 53 Therefore, target organ damage of SS could be mediated via inflammatory effects of aldosterone excess 54 and through recruitment of the mitogenic and fibroblast-stimulating actions of both isoprostanes 55, 56 and endothelin 52, 57 by aldosterone-induced oxidative stress.
Perspectives
Our observations that salt is capable of acutely increasing isoprostanes in humans and that this phenomenon is peculiar to SS hypertension, have at least 3 major implications. First, we show that isoprostanes, accurate markers of in vivo lipid oxidation that have been used to understand the contribution of oxidative stress to human atherosclerosis, hepatorenal syndrome, and neurodegenerative disorders, are also useful to identify features linked to oxidative stress in essential hypertension, a prevalent disease. This should stimulate research on the kinetics of the relationship between free and esterified isoprostanes and their rates and modes of exchange between compartments (ie, cells, plasma, and urine) for application to future research in humans. Second, we clearly demonstrate different effects of salt on putative mechanisms of target organ damage in at least 1 hypertensive intermediate phenotype. Hence, future epidemiological studies on the effects of salt on cardiovascular outcomes will have to characterize the intermediate phenotypes of the populations studied to resolve the ongoing controversy on the relationship between salt and morbidity. Third, our study shows that it is possible to identify hypertensive subjects in whom oxidative stress may be a major determinant of end-organ damage. Targeting of these subjects in clinical trials of antioxidant therapies may facilitate the discovery of effective agents, an achievement that has been somewhat elusive to date. The possibility that blockers of the mineralocorticoid receptor may constitute specific therapy for hypertension with exaggerated oxidative stress should also be investigated.
